Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: VAY736 placeboBiological: VAY736
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT02675803
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02672358
Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Behavioral: Lifestyle intervention
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT02670928
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: AIN457 (secukinumab)Drug: Placebo
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT02662985
- Locations
- 🇬🇧
Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Phase 2
Terminated
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Procedure: Bone marrow aspirate
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT02663752
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1002
- Registration Number
- NCT02661217
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Phase 2
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: Ligelizumab
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 226
- Registration Number
- NCT02649218
- Locations
- 🇬🇧
Novartis Investigative Site, Yeovil, Somerset, United Kingdom
Rainbow Extension Study
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT02640664
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
Phase 4
Withdrawn
- Conditions
- Wet Age-related Macular Degeneration (Wet AMD)
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02634970
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02634983
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom